Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$30.0K+275.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Zhenya Lindgardt
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 72
- Beta
- 0.98
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -4.57
Financials
Revenue
$30.0K+275.0%Net Income
$-9.14MEBITDA
$-8.97MFree Cash Flow
$-6.33MEPS (diluted)
$-0.18Shares Outstanding (diluted)
50.48M+178.8%Operating Expenses
$9.98MCash & Debt
$46.45MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $81.0K | $-31.93M | $-0.67 |
| 2024 | $77.0K | $-32.90M | $-0.99 |
| 2023 | $306.0K | $-36.24M | $-1.16 |
| 2022 | $268.0K | $-44.19M | $-1.43 |
| 2021 | $82.0K | $-35.01M | $-1.18 |
| 2020 | $25.0K | $-19.85M | $-1.19 |
| 2019 | $36.0K | $-16.52M | $-1.13 |
Valuation
SERAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-66.67%Social Signal Score
Mentions (5)
- Newsprnewswire.com·47d ago·Neutral
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been appointed Chief Financial Officer (CFO), effective August 31, 2026. Mr. Gleason brings more than 25 years of healthcare, diagnostics, and capital markets…
View source ↗ - Newsmarketbeat.com·54d ago·Neutral
Sera Prognostics Q2 Earnings Call Highlights Sera Prognostics NASDAQ: SERA reported modest second-quarter revenue while outlining progress in payer engagement, Illinois Medicaid policy, clinical evidence and European regulatory preparations for its PreTRM Test-guided care platform.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·54d ago·Negative
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.16 per share a year ago.
View source ↗ - Newsprnewswire.com·54d ago·Neutral
SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS SALT LAKE CITY, Aug. 12, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2026. Key Second Quarter and Recent Highlights: Advanced Commercial Adoption Strategy with Fourth Partnership Program Launch:
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.14 per share
Typical surprise +5.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.18 vs $-0.15miss
- Wed, May 6$-0.17 vs $-0.16miss
- Wed, Mar 18$-0.16 vs $-0.17beat
- Thu, Nov 13$-0.16 vs $-0.19beat
- Wed, Aug 6$-0.16 vs $-0.21beat
- Wed, May 7$-0.20 vs $-0.24beat
Estimates and results for SERA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SERA officers and directors.
- Bought
- —
- Sold
- $563k
0 trades
45 trades
- Anderson Dyaarl Lee Jr.sold
- Lindgardt Zhenyasold
- Inglis Tiffany Eul Davissold
- Jackson Benjaminsold
- Lindgardt Zhenyasold
- Anderson Dyaarl Lee Jr.sold
- Aerts Austinsold
- Lindgardt Zhenyasold
55 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SERA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.